Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting
Jingyi Yang, Hao Guo, Lu Han, Yongping Song, Keshu Zhou
Abstract
Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely used approaches include CD19/CD20, CD20/CD22, and BCMA/CD19 CAR T-cells. Alternative immune cells, including natural killer T cells and invariant natural killer T cells, exhibit innate anti-tumor activity and reduced toxicity. This review summarizes several recent clinical trial reports and preclinical studies from the 2023 American Society of Hematology (ASH) annual meeting on dual-targeted CAR T-cell immunotherapy for hematological malignancies.
Topics & Concepts
Chimeric antigen receptorMedicineHematologyImmunotherapyCD20CD19ImmunologyAntigenOncologyInternal medicineImmune systemCancer researchCAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses